AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-305-671-0200</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

Drug Requested: dichlorphenamide (Keveyis®)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.		
Member Name:		
Member AvMed #:	Date of Birth:	
Prescriber Name:		
	Date:	
Office Contact Name:		
Phone Number:	Fax Number:	
DEA OR NPI #:		
DRUG INFORMATION: Au	thorization may be delayed if incomplete.	
Drug Form/Strength:		
	Length of Therapy:	
Diagnosis:	ICD Code, if applicable:	
Weight:	Date:	
weekly intervals (or more frequently	nitial: 50 mg once or twice daily; may increase or decrease dosage at in response to adverse reactions); minimum: 50 mg/day; maximum: 200 for continued therapy after 2 months of treatment	
Quantity Limit: 120 tablets per 3	30 days	
	ck below all that apply. All criteria must be met for approval. To nentation, including lab results, diagnostics, and/or chart notes, must be	
Initial Authorization: 12 mon	nths	
☐ Member is 18 years of age or	older	
· · · · · · · · · · · · · · · · · · ·	on with a neurologist or a physician who specializes in the care of odic paralysis (e.g., muscle disease specialist, physiatrist)	

(Continued on next page)

	☐ Member has a diagnosis of primary periodic paralysis confirmed by BOTH of the following:	
	☐ Genetic testing for confirmation of SCN4 or CACNA1S mutation	
	☐ Electromyography confirming absence of myotonic discharges	
	Provider has submitted lab or chart note confirmation to support <u>ONE</u> of the following: □ If diagnosis is hypokalemic periodic paralysis: Serum K < 3.5 mEq/L during attack OR family history of condition	
	☐ If diagnosis is hyperkalemic periodic paralysis: Serum K > 5.0 mEq/L during attack OR increased serum K > 1.5 mEq/L during attack OR family history of condition	
	Member has had an inadequate response to a trial of acetazolamide at a dose of 125-1500 mg/day for at least 60 days within a year of request <u>OR</u> has a documented contraindication to acetazolamide (verified by chart notes or pharmacy paid claims; inadequate response is defined as no reduction in number of attacks per month after receiving treatment with acetazolamide at recommended doses)	
	Provider has submitted chart notes documenting member's baseline number of attacks per month prior to acetazolamide therapy:	
	Baseline values for frequency and severity of attacks of muscle weakness experienced after beginning acetazolamide therapy has been submitted (necessary for renewal):	
	Member continues to have paralytic attacks despite dietary intervention and avoidance of trigger	
uppo	uthorization: 12 months. Check below all that apply. All criteria must be met for approval. To ort each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be ded or request may be denied.	
	Member has experienced disease response as indicated by a decrease in the frequency and/or severity of attacks of muscle weakness from pre-treatment baseline	
	Member has <u>NOT</u> experienced unacceptable toxicity from the drug (e.g., hypersensitivity reactions, hypokalemia, metabolic acidosis, falls)	
Iedi	cation being provided by Specialty Pharmacy - PropriumRx	

Use of samples to initiate therapy does not meet step edit/preauthorization criteria.

Previous therapies will be verified through pharmacy paid claims or submitted chart notes.